Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Summit Therapeu ADR (NQ: SMMT )

4.390 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, May 21, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,090
Open 4.390
Bid (Size) 4.390 (1)
Ask (Size) 4.500 (2)
Prev. Close 4.390
Today's Range 4.390 - 4.390
52wk Range 1.500 - 5.390
Shares Outstanding 97,381,774
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Tempur Sealy Posts Upbeat Earnings, Joins FibroGen, Coca-Cola Consolidated, Fabrinet And Other Big Stocks Moving Higher On Tuesday
Via Benzinga
SMMT Stock Earnings: Summit Therapeutics Reported Results for Q1 2024
Summit Therapeutics just reported results for the first quarter of 2024. 
Via InvestorPlace

Performance

YTD
+66.29%
+66.29%
1 Month
+25.79%
+25.79%
3 Month
+17.38%
+17.38%
6 Month
+121.72%
+121.72%
1 Year
+176.10%
+176.10%

More News

Read More
Summit Therapeutics Reports Financial Results and Operational Progress for the First Quarter Ended March 31, 2024
From Summit Therapeutics Inc.
Via Business Wire
Summit Therapeutics to Host First Quarter 2024 Financial Results & Operational Progress Call on May 1, 2024
From Summit Therapeutics Inc.
Via Business Wire
Summit Therapeutics Appoints Dr. Mostafa Ronaghi, Renowned Executive and Genomicist, to its Board of Directors
From Summit Therapeutics Inc.
Via Business Wire
Summit Therapeutics to Present at the Stifel 2024 Targeted Oncology Forum
From Summit Therapeutics Inc.
Via Business Wire
Why Summit Therapeutics Stock Crushed the Market This Week
Via The Motley Fool
Why Kodiak Sciences Shares Are Trading Lower By Around 20%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Via Benzinga
Akeso Marks Profit Milestone With Swift Rights Issue
Via Benzinga
Analysts Eye Summit Therapeutics' Ivonescimab As Potential Challenger To Merck's Keytruda in Lung Cancer Treatment
Via Benzinga
Tesla, Krispy Kreme, McCormick And Other Big Stocks Moving Higher On Tuesday
Via Benzinga
Topics Stocks
Exposures US Equities
Intracranial Anti-Tumor Activity and Safety of Ivonescimab in NSCLC Patients with Brain Metastases to be Featured at ELCC 2024
From Summit Therapeutics Inc.
Via Business Wire
Why Science Applications International Shares Are Trading Lower By Over 10%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Via Benzinga
Summit Therapeutics to Present at the Barclays 26th Annual Global Healthcare Conference
From Summit Therapeutics Inc.
Via Business Wire
Why Clover Health Investments Shares Are Trading Higher By 11%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Via Benzinga
Surgery Partners Posts Weak Sales, Joins Kosmos Energy, Moderna And Other Big Stocks Moving Lower On Monday
Via Benzinga
Topics Stocks
Exposures US Equities
Summit Therapeutics Inc. (SMMT) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings
From Bronstein, Gewirtz & Grossman, LLC
Via Business Wire
Crude Oil Moves Lower; Summit Therapeutics Shares Plummet
Via Benzinga
Topics Stocks
Exposures Fossil Fuels US Equities
12 Health Care Stocks Moving In Tuesday's Intraday Session
Via Benzinga
Dow Dips Over 100 Points; US Leading Economic Index Falls In January
Via Benzinga
Topics Stocks
Exposures US Equities
Why Fluor Shares Are Trading Lower By Around 8%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Via Benzinga
Summit Therapeutics Reports Financial Results and Operational Progress for the Fourth Quarter and Year Ended December 31, 2023
From Summit Therapeutics Inc.
Via Business Wire
Earnings Scheduled For February 20, 2024
Via Benzinga
Summit Therapeutics to Host Fourth Quarter & Full Year 2023 Financial Results & Operational Progress Call on February 20, 2024
From Summit Therapeutics Inc.
Via Business Wire
Summit Therapeutics to Present at Oppenheimer’s 34th Annual Healthcare Life Sciences Conference
From Summit Therapeutics Inc.
Via Business Wire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.